GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):



	December 31, 2017		Currency translation adjustments			June 30, 2018
CHCA	$	1,847.4	$	(2.0	)	$	1,845.4
CHCI	1,205.7		(30.6		)	1,175.1
RX	1,122.3		(5.3		)	1,117.0
Total goodwill	$	4,175.4	$	(37.9	)	$	4,137.5

Animal Health

Following a prior indication of potential impairment during the three months ended December 31, 2017, the animal health reporting unit had an additional indication of potential impairment during the three month ended June 30, 2018 due to its year-to-date financial results failing to meet performance expectations. We performed an impairment test as of June 30, 2018 and determined the fair value of the animal health reporting unit exceeded its net book value and therefore, no impairment was recorded as of the three months ended June 30, 2018.

Intangible Assets

Other intangible assets and related accumulated amortization consisted of the following (in millions):



	June 30, 2018				December 31, 2017
	Gross		Accumulated Amortization		Gross		Accumulated Amortization
Definite-lived intangibles:
Distribution and license agreements and supply agreements	$	310.0	$	188.3	$	311.2	$	169.8
Developed product technology, formulations, and product rights	1,349.8		647.0		1,358.4		598.7
Customer relationships and distribution networks	1,608.7		513.2		1,642.0		460.6
Trademarks, trade names, and brands	1,304.3		159.8		1,335.4		129.5
Non-compete agreements	14.5		13.0		14.7		12.6
Total definite-lived intangibles	$	4,587.3	$	1,521.3	$	4,661.7	$	1,371.2
Indefinite-lived intangibles:
Trademarks, trade names, and brands	$	51.7	$	—	$	52.1	$	—
In-process research and development	37.9		—		38.2		—
Total indefinite-lived intangibles	89.6		—		90.3		—
Total other intangible assets	$	4,676.9	$	1,521.3	$	4,752.0	$	1,371.2

We recorded amortization expense of $85.3 million and $172.4 million for the three and six months ended June 30, 2018, respectively, and $87.2 million and $172.8 million for the three and six months ended July 1, 2017, respectively.

We recorded an impairment charge of $12.2 million on certain In-process Research and Development ("IPR&D") assets, primarily in our RX segment, during the three months ended April 1, 2017 due to changes in the projected development and regulatory timelines for various projects. In addition, we recorded a decrease in the contingent consideration liability associated with certain IPR&D assets in Other operating expense (income) on the Condensed Consolidated Statements of Operations (refer to Note 6).

During the three months ended July 1, 2017, we identified impairment indicators for our Lumara Health, Inc. product assets. The primary impairment indicators included the decline in our 2017 performance expectations and a reduction in our long-range revenue growth forecast. As part of our assessment, we utilized the multi-period excess earnings method to determine fair value. This resulted in an impairment charge of $18.5 million in Impairment charges on the Condensed Consolidated Statements of Operations within our RX segment, which represented the difference between the carrying amount of the intangible assets and their estimated fair value.